Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

Core Insights - Xenon Pharmaceuticals Inc. is hosting an investor webinar on December 10, 2025, to present data from the American Epilepsy Society Annual Meeting, focusing on long-term data from the X-TOLE study of azetukalner and real-world data on depression in epilepsy [1][2] - Azetukalner is a novel Kv7 potassium channel opener currently in Phase 3 clinical trials for epilepsy, major depressive disorder, and bipolar depression [3] Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of therapeutics [3] - The company is advancing a portfolio of potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for pain treatment [3] Webinar Details - The webinar will take place from 10:00 to 11:00 AM Eastern Time, with a live webcast available on the company's website [2] - Participants can submit questions via chat during the webinar or in advance via email [2]